Advertisement

Topics

FDA Lifts Clinical Hold on Advaxis’ Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab

09:52 EDT 13 Jul 2018 | Speciality Pharma Journal

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Investigational New Drug (IND) application for its Phase 1/2 study of axalimogene filolisbac (AXAL) in combination with durvalumab for …

Original Article: FDA Lifts Clinical Hold on Advaxis’ Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab

NEXT ARTICLE

More From BioPortfolio on "FDA Lifts Clinical Hold on Advaxis’ Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...